PMV Pharmaceuticals, Inc. (PMVP) stock
PMVPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.22+0.03 (+2.52%)
Close on Nov 17, 2026Market cap $65.22MP/E –Yield –
PMV Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
PMV Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $64.04M, down 3.8% year over year. For fiscal 2025 it was $69.88M, up 19.4% from the year before. The highest annual figure on record is $69.88M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.88M | +19.4% |
| FY2024 | Dec 31, 2024 | $58.53M | +4.7% |
| FY2023 | Dec 31, 2023 | $55.89M | +7.5% |
| FY2022 | Dec 31, 2022 | $51.99M | +42.5% |
| FY2021 | Dec 31, 2021 | $36.49M | +52.5% |
| FY2020 | Dec 31, 2020 | $23.93M | +15.3% |
| FY2019 | Dec 31, 2019 | $20.76M | +49.9% |
| FY2018 | Dec 31, 2018 | $13.85M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $14.68M | -20.2% |
| Q1 FY2026 | Mar 31, 2026 | $15.33M | -12.1% |
| Q4 FY2025 | Dec 31, 2025 | $15.83M | +15.0% |
| Q3 FY2025 | Sep 30, 2025 | $18.21M | +7.5% |
| Q2 FY2025 | Jun 30, 2025 | $18.40M | +25.8% |
| Q1 FY2025 | Mar 31, 2025 | $17.44M | +32.3% |
| Q4 FY2024 | Dec 31, 2024 | $13.77M | +2.9% |
| Q3 FY2024 | Sep 30, 2024 | $16.95M | +24.7% |
| Q2 FY2024 | Jun 30, 2024 | $14.63M | +5.7% |
| Q1 FY2024 | Mar 31, 2024 | $13.19M | -12.5% |
| Q4 FY2023 | Dec 31, 2023 | $13.38M | -10.9% |
| Q3 FY2023 | Sep 30, 2023 | $13.59M | -0.6% |
| Q2 FY2023 | Jun 30, 2023 | $13.84M | +20.8% |
| Q1 FY2023 | Mar 31, 2023 | $15.07M | +27.3% |
| Q4 FY2022 | Dec 31, 2022 | $15.03M | +23.5% |
| Q3 FY2022 | Sep 30, 2022 | $13.67M | +49.2% |
| Q2 FY2022 | Jun 30, 2022 | $11.46M | +49.6% |
| Q1 FY2022 | Mar 31, 2022 | $11.84M | +57.8% |
| Q4 FY2021 | Dec 31, 2021 | $12.17M | +96.8% |
| Q3 FY2021 | Sep 30, 2021 | $9.16M | +52.9% |
| Q2 FY2021 | Jun 30, 2021 | $7.66M | +32.0% |
| Q1 FY2021 | Mar 31, 2021 | $7.50M | +25.9% |
| Q4 FY2020 | Dec 31, 2020 | $6.18M | +8.5% |
| Q3 FY2020 | Sep 30, 2020 | $5.99M | +22.4% |
| Q2 FY2020 | Jun 30, 2020 | $5.80M | – |
| Q1 FY2020 | Mar 31, 2020 | $5.96M | – |
| Q4 FY2019 | Dec 31, 2019 | $5.70M | – |
| Q3 FY2019 | Sep 30, 2019 | $4.90M | – |
See a number that looks wrong?